Zobrazeno 1 - 10
of 72
pro vyhledávání: '"C, Iniesta Navalón"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
AM Martínez Soto, M García Coronel, C Pastor Mondéjar, JM Marco Puig, P Ortiz Fernandez, P Fernández-Villacañas Fernández, C Caballero Requejo, L Rentero Redondo, C Iniesta Navalón, I Salar Valverde, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a51dea737afaa4f49a67ad656cbd514e
https://doi.org/10.1136/ejhpharm-2022-eahp.266
https://doi.org/10.1136/ejhpharm-2022-eahp.266
Autor:
C Pastor Mondéjar, C Iniesta Navalón, A Martinez Soto, P Ortiz Fernandez, P Ferandez-Villacañas Ferandez, L Rentero Redondo, C Caballero Requejo, M Garcia Coronel, I Salar Valverde, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff803a5274a4b6280b898b7e5f3ed348
https://doi.org/10.1136/ejhpharm-2022-eahp.351
https://doi.org/10.1136/ejhpharm-2022-eahp.351
Autor:
C Pastor Mondéjar, C Iniesta Navalón, A Martínez Soto, P Ortiz Fernández, P Ferandez-Villacañas Ferandez, I Salar Valverde, L Rentero Redondo, C Caballero Requejo, M Garcia Coronel, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efee6b8a690f7c8407248174c98af5c6
https://doi.org/10.1136/ejhpharm-2022-eahp.314
https://doi.org/10.1136/ejhpharm-2022-eahp.314
Autor:
L. Villamayor Blanco, G. Llimera Rausell, V. Jorge Vidal, C. González Pérez-Crespo, C. Iniesta Navalón, M.ª C. Mira Sirvent, M. Martínez Penella, S. Rabell Íñigo
Publikováno v:
Nutrición Hospitalaria, Vol 21, Iss 2, Pp 163-172 (2006)
Antecedentes y Objetivos: Las altas cifras iniciales de prevalencia de desnutrición en los enfermos hospitalizados-cercanos al 40%- es un dato preocupante. Esto permite deducir que la identificación precoz de enfermos desnutridos o en riesgo de est
Externí odkaz:
https://doaj.org/article/b2f0ffe9fd5c4ce886188b45bfd3833e
Autor:
C Iniesta Navalón, C Pastor Mondéjar, M García Coronel, AM Martínez Soto, I Salar Valverde, L Rentero Redondo, Mdc Caballero Requejo, M Gil Candel, P Ortíz Fernández, E Urbieta Sanz, M Onteniente Candela
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Adalimumab is a human monoclonal recombinant antibody whose mechanism of action is mediated by binding specifically to tumour necrosis factor (TNF), neutralising its function. Adalimumab is indicated for the treatment of pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87ac00c26bdd66fc1ea5c6ab1b9d970
https://doi.org/10.1136/ejhpharm-2021-eahpconf.158
https://doi.org/10.1136/ejhpharm-2021-eahpconf.158
Autor:
C Iniesta Navalón, C Pastor Mondéjar, Mdc Caballero Requejo, M García Coronel, I Salar Valverde, AM Martínez Soto, E Urbieta Sanz, M Gil Candel, P Ortíz Fernández, A Quesada Asencio, M Onteniente Candela
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Rheumatoid arthritis is a chronic, autoimmune disease, with unknown aetiology, characterised by chronic inflammation of synovial articulations. Biologic disease modifying antirheumatic drugs (bDMARDs) are used to slow down d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ebf5883cde6f83ba5de670ae212e3cc
https://doi.org/10.1136/ejhpharm-2021-eahpconf.298
https://doi.org/10.1136/ejhpharm-2021-eahpconf.298
Autor:
C Iniesta Navalón, AM Martínez Soto, L Rentero Redondo, I Salar Valverde, Mdc Caballero Requejo, M Onteniente Candela, M Gil Candel, P Ortíz Fernández, A Quesada Asencio, E Urbieta Sanz, C Pastor Mondéjar
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Etanercept is a fusion protein composed of the p75 receptor of tumour necrosis factor (TNF) and the Fc portion of human immunoglobulin. It is indicated for the treatment of diseases such as rheumatoid arthritis, ankylosing s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c7534f21ab30b87349d4a9a527739cd
https://doi.org/10.1136/ejhpharm-2021-eahpconf.295
https://doi.org/10.1136/ejhpharm-2021-eahpconf.295
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Gil Candel, M I Nicolás de Prado, C Iniesta Navalón, JJ Martínez Crespo, L Rentero Redondo, L Serrano Díaz, R M Gómez Espín
Publikováno v:
Journal of Crohn's and Colitis. 14:S449-S450
Background Ustekinumab (UTK) is a human immunoglobulin (Ig) G1 kappa monoclonal antibody approved in 2017 for the treatment of Crohn’s Disease (CD). Up until now, there has not been enough evidence of the relationship between ustekinumab trough lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60758ed7489028041733e01a5b2bbe32
https://doi.org/10.1093/ecco-jcc/jjz203.648
https://doi.org/10.1093/ecco-jcc/jjz203.648